Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dexamethasone Intra-Erythrocyte Therapy in Patients With Chron's Disease or Ulcerative Colitis
Brief Summary: Objectives:

The primary objective of this trial was to evaluate the patients response rate at the end of the study.

Patients were considered responder if one of the following conditions occurs:

* Disease remission (Powell Tuck ≤ 3 or CDAI \< 150) and withdrawal of oral steroids therapy from at least the second treatment procedure;
* Disease marked improvement versus basal conditions (at least 5 point decrease in Powell Tuck index or 150 point decrease in CDAI score) and withdrawal of oral steroids therapy from at least the second treatment procedure.

Secondary objectives:

* to evaluate the endogenous cortisole production after receiving the study treatment
* to evaluate the inflammatory indexes (ESR and CPR) after receiving the study treatment
* to evaluate the endoscopic remission in patients suffering from mesalazine refractory Ulcerative Colitis
* to evaluate the safety of dexamethasone intra-erythrocyte therapy with particular attention to steroid-related adverse events.


Options:
A: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Open Label; Type: OTHER; Interventions: Drug: Anti-IP-10 Antibody | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction, Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 1: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Open Label
B: Arm Label: Asacol 2.4 g/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg (mesalamine) | Arm Label: Asacol 4.8 g/day; Type: EXPERIMENTAL; Interventions: Drug: Asacol 800 mg (mesalamine) | Intervention Type: DRUG; Name: Asacol 800 mg (mesalamine); Assigned to Arm(s): Asacol 4.8 g/day | Intervention Type: DRUG; Name: Asacol 400 mg (mesalamine); Assigned to Arm(s): Asacol 2.4 g/day
C: Arm Label: Dex 21-P; Type: EXPERIMENTAL; Interventions: Drug: Dex 21-P | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dex 21-P; Assigned to Arm(s): Dex 21-P | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Abatacept (ABA); Type: EXPERIMENTAL; Interventions: Drug: abatacept (ABA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: abatacept; Type: OTHER; Interventions: Drug: abatacept | Intervention Type: DRUG; Name: abatacept (ABA); Assigned to Arm(s): Abatacept (ABA) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): abatacept

Answer: C